

# Thyroid microcarcinoma during thyroidectomy

Siassakos D, Gourgiotis S, Moustafellos P, Dimopoulos N, Hadjiyannakis E

## ABSTRACT

**Introduction:** We aimed to assess in a retrospective study the prevalence of microcarcinoma in thyroidectomy specimens from a Greek population and the role of histopathology in determining management for these patients.

**Methods:** We used histopathological reports of thyroidectomies performed in a Greek general district hospital. The samples were consisted of 191 thyroidectomies performed between January 1997 and July 2001. The female/male ratio was approximately 2:1 and the follow-up period was 327 weeks.

**Results:** There were 29 microcarcinomas (15.2 percent) with a female:male ratio of 6:1. The prevalence rate in cases with Hashimoto lymphocytic thyroiditis was significantly higher compared to cases with other benign thyroid pathology (26.8 percent versus 11.9 percent, p-value equals 0.02). Eight microcarcinomas (27.6 percent) were multifocal. The histological type was that of papillary tumour in ten cases (34.5 percent) and follicular in 18 cases (62.1 percent). There were no deaths, recurrences or metastases during the follow-up period.

**Conclusion:** Our evidence suggests that incidental microcarcinomas are low-risk tumours that do not require routine further intervention. The latter may be necessary for tumours with poor differentiation or for non-incidental microcarcinomas.

**Keywords:** thyroid carcinoma, thyroid microcarcinoma, thyroidectomy

Singapore Med J 2008; 49 (1):xxxxxx

## INTRODUCTION

Thyroid microcarcinoma is defined as a malignant tumour of < 1 cm or less papillary carcinoma.<sup>(1)</sup> Some authors have extended the definition to include tumours of up to

15 mm.<sup>(2,3)</sup> Such tumours can be discovered by neck ultrasonography or incidentally after histopathological examination of thyroidectomy specimens.<sup>(4,5)</sup> The latter are called “incidentalomas”.<sup>(5)</sup> The prevalence varies; most autopsy studies place it in the range of 4.7%–9.9%,<sup>(6,7)</sup> but rates as high as 35%–36% have also been reported.<sup>(8)</sup> In thyroidectomy specimens, the prevalence ranges from 11% to 35.3%.<sup>(3,4,9)</sup> A higher rate among male subjects has also been reported in the literature, with a male:female ratio ranging from 6:4 to 8:3.<sup>(6,7)</sup> There has been considerable debate in the literature about the significance of these occult tumours. Some authors believe that they should be treated as benign,<sup>(8)</sup> while others deem that aggressive management with radioiodine ablation of any thyroid tissue remnants is necessary.<sup>(5)</sup> We aimed to examine a Greek population to establish the characteristics of these tumours and the implications for subsequent management.

## METHODS

Our material was consisted of the histopathological reports of thyroidectomies performed in the surgical department of a central Greek general district hospital located in the capital. We also assessed the relevant operating and patient notes from our archives. The samples were consisted of 191 thyroidectomies performed by three different consultant firms between January 1997 and July 2001. The female:male ratio was approximately 2:1 in our samples (122 and 69, respectively) and the follow-up period was 327 weeks. Follow-up was clinical (six-monthly intervals). The surgical specimens were fixed in 10% buffered formaldehyde, adequately sampled, embedded in paraffin, and cut into sections 5 µm thick. The sections were then stained with hematoxylin-eosin. We decided to use the 15 mm maximum diameter cut-off for our study as we were particularly interested in the incidental nature of microcarcinomas rather than their size. A follicular tumour was considered to be a microcarcinoma when there was capsular or vascular invasion. We used the chi-squared test. A p-value < 0.05 was considered to be statistically significant.

## RESULTS

Of the 191 thyroidectomies, 16 (8.4%) were performed for clinically suspected or histologically (fine-needle aspiration

Department of Obstetrics and Gynaecology, Southmead University Hospital, Westbury-on-Trym, Bristol, BS10 5NB, The United Kingdom [CORRESPONDING AUTHOR TO VERIFY ACCURACY OF ADDRESS AND PROVIDE DESIGNATION]

Siassakos D, MBBS, MSc

First Surgical Department, Evangelismos General Hospital of Athens, 45-47 Ypsilantou Str, 10676 Athens, Greece [CORRESPONDING AUTHOR TO VERIFY ACCURACY OF ADDRESS AND PROVIDE DESIGNATIONS OF ALL AUTHORS]

Gourgiotis S, MD, PhD

Moustafellos P, MD, PhD

Dimopoulos N, MD

Hadjiyannakis E, MD, PhD, FRCS

**Correspondence to:** Dr Stavros Gourgiotis Zakinthinou 41, 15669 Papagou, Athens, Greece  
Tel: (30) 210 652 5802 [AUTHOR TO CONFIRM THAT TEL AND FAX NO ARE CORRECT]  
Fax: (30) 210 652 5802  
Email: drsgourgiotis@tiscali.co.uk; goustaro@otenet.gr

[FNA]) confirmed cancer. 175 (91.6%) were performed for benign disease (e.g. goitre, solitary nodules) of which 41 (21.5% of the total) were diagnosed postoperatively as being Hashimoto lymphocytic thyroiditis. There were 29 microcarcinomas (15.2%) discovered incidentally in the histopathological examination of the specimens, all less than 15 mm in diameter (range 0.1–15 mm). There were no incidental tumours of larger size. The female:male ratio was 6:1 (25 and four patients, respectively). The relevant procedures were consisted of total thyroidectomy in 20 cases (69%), near-total thyroidectomy in 7 (24.1%), sub-total thyroidectomy in one and unilateral lobectomy in one case. The indications for surgery and the prevalence of microcarcinoma are shown in Table I.

The prevalence rate of microcarcinoma in patients with Hashimoto lymphocytic thyroiditis was the highest (26.8%),

and when compared with other benign cases (11.9%), the difference was statistically significant ( $p = 0.02$ ). A total of 8 microcarcinomas (27.6%), were multifocal with 2–9 separate foci, 4/11 (36.6%) in Hashimoto specimens and 4/18 (22.2%) in non-Hashimoto. Of those tumours, 7 (24.1%) involved both thyroid gland lobes. The histological type was that of papillary tumour in ten cases (34.5%), follicular in 18 cases (62.1%), and one (3.45%) was an incidental medullary tumour of 15 mm size in a thyroid gland excised for goitre (Table II). One of the tumours was of the tall-cell variant. There was one case of malignant infiltration of lymph nodes, but that was in a known cancer case. There was one additional case with extrathyroidal extension of the incidental carcinoma. It involved the tall-cell variant tumour, consisting of two separate foci of 5 and 7 mm, respectively. There were no deaths, recurrences or metastases during the follow-up period.

**Table I.**

Primary indication	No. of patients	No. of patients with microcarcinoma (%)
Thyroid cancer	16	2 (12.5)
Solitary nodules	37	3 (8.1)
Goitre total	138	24 (17.4)
Goitre (excluding Hashimoto)	97	13 (13.4)
Hashimoto lymphocytic thyroiditis (postoperative diagnosis)	41	11 (26.8 <sup>*</sup> )
All benign cases (excluding Hashimoto)	134	16 (26.8 <sup>*</sup> )
<b>Total</b>	<b>191</b>	<b>29 (26.8<sup>*</sup>)</b>

**Table II. Histological type of incidental microcarcinom**

Histological type	No. of patients
Papillary	10
Follicular	18
Medullary	1

## DISCUSSION

Our findings suggest a high prevalence of incidental microcarcinoma, frequently multifocal, in specimens removed for benign or known malignant disease. We elected to include tumours of less than 15 mm in our study as our objective was to focus on their incidental nature. Three of the microcarcinomas and one of the foci in a multifocal tumour were 10–15 mm. Interestingly, our results demonstrate a higher rate of follicular rather than papillary tumours. This was also the case in a previous large study in Greece.<sup>(10)</sup> A moderate degree of iodine deficiency which is still persisting in Greece may be responsible; since it has been shown to increase the follicular/papillary tumour ratio.<sup>(11)</sup> Histological criteria may also play a role, as follicular tumours will often be reclassified as papillary on histological review.<sup>(12)</sup> Similar questions arise regarding our very high female/male (6:1) ratio which contrasts with

that in most other studies<sup>(6,7)</sup> but is similar with findings of other studies in Greece.<sup>(10)</sup> This ratio appears to be generally high in thyroidectomies -and thyroid diseases- in our population, as demonstrated by the 2:1 ratio in our initial sample.

The prevalence of microcarcinoma was particularly high in specimens with Hashimoto disease. It has been demonstrated that Hashimoto is associated with Warthin-like papillary tumours.<sup>(13)</sup> In a series of 17 such tumours, a background of lymphocytic thyroiditis was identified. Seven cases had other microcarcinoma foci as well. This demonstrates a possible immune mechanism as a pathogenetic factor for development of thyroid tumours.<sup>(14)</sup> There were no deaths, recurrences or metastases among our patients but it must be noted that our samples were consisted of asymptomatic, incidental tumours. However, we had one case with malignant lymph node infiltration but as mentioned above that was a known cancer case. Studies that have demonstrated metastases or recurrences include incidental, known (by FNA) and suspected (lymph node involvement) microcarcinomas.<sup>(1,15-17)</sup> Nevertheless, even when symptomatic, non-incidental tumours are included in the analysis, and with follow-up periods of up to eight<sup>(1,14)</sup> or 20 years,<sup>(12)</sup> recurrence rate is low and in the area of 4%–6%,<sup>(1,15,16)</sup> and related deaths are very rare,<sup>(15)</sup> even if the observation only is the chosen management option.<sup>(1)</sup>

Lymph node involvement at initial presentation is the strongest clinical predictor of recurrence, whereas the evidence about the role of the extent of surgery or radioiodine treatment is conflicting.<sup>(1,15,16)</sup> Immunohistological positivity for Cyclin-D1,<sup>(18)</sup> Ki-67 and TGFbeta3<sup>(19)</sup> is also a potential indicator of aggressiveness and metastasising behaviour. Tall-cell variants are examples of poor differentiation, which in turn is a strong predictor of aggressiveness and recurrence.<sup>(19)</sup> Incidental medullary tumours, on the other hand, seem to be sporadic<sup>(20)</sup> rather than familial, and not related to unfavourable outcomes. Such outcomes seem to be limited to symptomatic medullary microcarcinomas only.<sup>(21)</sup> In conclusion, we believe that incidental microcarcinomas are low-risk, “laboratory” tumours that do not routinely require further surgical, radiotherapeutic intervention or follow-up. Additional intervention may however be necessary for tumours with poor differentiation, evidence of extrathyroidal extension, the presence of immunohistological aggressiveness markers, or for non-incidental microcarcinomas. Regarding Hashimoto and microcarcinoma, further research is needed to clarify the links between the two entities.

## REFERENCES

- Ito Y, Urano T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. *Thyroid* 2003; 13:381-7.
- Arem R, Padayatty SJ, Saliby AH, Sherman SI. Thyroid microcarcinoma: prevalence, prognosis, and management. *Endocr Pract* 1999; 5:148-56.
- Biscolla RP, Ugolini C, Sculli M, et al. Medullary and papillary tumours are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behaviour. *Thyroid* 2004; 14:946-52.
- Carlini M, Giovannini C, Castaldi F, et al. High risk for microcarcinoma in thyroid benign diseases. Incidence in a one year period of total thyroidectomies. *J Exp Clin Cancer Res* 2005; 24:231-6.
- Dietlein M, Luyken WA, Schicha H, Larena-Avellaneda A. Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough? *Nucl Med Commun* 2005; 26:3-8.
- Kovács GL, Gonda G, Vadász G, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. *Thyroid* 2005; 15:152-7.
- Neuhold N, Kaiser H, Kaserer K. Latent carcinoma of the thyroid in Austria: a systematic autopsy study. *Endocr Pathol* 2001; 12:23-31.
- Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systemic autopsy study. *Cancer* 1985; 56:531-8.
- Furlan JC, Rosen IB. Prognostic relevance of previous exposure to ionizing radiation in well-differentiated thyroid cancer. *Langenbecks Arch Surg* 2004; 389:198-203.
- Tzavara I, Vlassopoulou B, Alevizaki C, et al. Differentiated thyroid cancer: a retrospective analysis of 832 cases from Greece. *Clin Endocrinol (Oxf)* 1999; 50:643-54.
- Vigneri R, Pezzino V, Squatrito S, et al. Iodine deficiency and thyroid cancer. In: Delange F, Robertson A, McLoughney E, Gerasimov G, eds. *Elimination of Iodine Deficiency Disorders (IDD) in Central and Eastern Europe, the Commonwealth of Independent States, and the Baltic States*. Geneva: WHO, 1998: 67-72.
- Verkooijen HM, Fioretta G, Pache JC, et al. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. *Cancer Causes Control* 2003; 14:13-7.
- Baloch ZW, LiVolsi VA. Warthin-like papillary carcinoma of the thyroid. *Arch Pathol Lab Med* 2000; 124:1192-5.
- Lucas-Martin A, Foz-Salam, Todd I, Bottazzo GF, Pujol-Borrell R. Occurrence of thyrocyte HLA class II expression in a wide variety of thyroid diseases: relationship with lymphocytic infiltration and thyroid autoantibodies. *J Clin Endocrinol Metab* 1988; 66:367-75.
- Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstrahl EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. *Surgery* 1992; 112:1139-46.
- Sugitani I, Yanagisawa A, Shimizu A, Kato M, Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. *World J Surg* 1998; 22:731-7.
- Yang GC, LiVolsi VA, Baloch ZW. Thyroid microcarcinoma: fine-needle aspiration diagnosis and histologic follow-up. *Int J Surg Pathol* 2002; 10:133-9.
- Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. *J Clin Endocrinol Metab* 2002; 87:1810-3.
- Piloti S, Collini P, Manzari A, Marubini E, Rilke F. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? *Semin Diagn Pathol* 1995; 12:249-55.
- Albores-Saavedra JA, Krueger JE. C-cell hyperplasia and medullary thyroid microcarcinoma. *Endocr Pathol* 2001; 12:365-77.
- Guyétant S, Dupre F, Bigorgne JC, et al. Medullary thyroid microcarcinoma: a clinicopathological retrospective study of 38 patients with no prior familial disease. *Hum Pathol* 1999; 30:957-63.